Could This Safe Play Help Eli Lilly & Co. (LLY)?
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Posts Tagged ‘NYSE:SNY’
Exploding Pipeline Makes BioMarin Pharmaceutical Inc. (BMRN) Attractive Takeover Target
The Orphan Drug pipeline of BioMarin Pharmaceutical Inc.
Could This Safe Play Help Eli Lilly & Co. (LLY)?
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
The Boeing Company (BA), Lockheed Martin Corporation (LMT) – Pentagon Watch: Where Did Your Tax Dollars Go This Week?
The U.S. military has a reputation as a somewhat secretive organization. But in one respect at least, the Pentagon ranks among our most transparent government agencies.
Aegerion Pharmaceuticals, Inc. (AEGR), NPS Pharmaceuticals, Inc. (NPSP): Three of the World’s Rarest Diseases (and the Uncommon Profits They Bring)
Imagine finding out that you have a disease that only a handful of people around the world have. Kirstie and Catherine Fields don't have to imagine it.
Dendreon Corporation (DNDN), Johnson & Johnson (JNJ), Medivation Inc (MDVN): The Most Expensive Drugs in the World
The prescription-drug market currently generates a whopping $950 billion in annual sales, and that figure is likely to grow to $1.2 trillion by 2016.
AstraZeneca plc (ADR) (AZN), Sanofi SA (ADR) (SNY): Don’t Ignore These European Healthcare Stocks
Healthcare stocks have rallied over the past couple years, and for good reason.
Sanofi SA (ADR) (SNY), Novo Nordisk A/S (ADR) (NVO), Johnson & Johnson (JNJ): Can Investors Bet on These 3 Pharma Companies?
It is expected that the death rate from diabetes will top 50% in the next ten years, which will make it a leading cause of death worldwide.
Johnson & Johnson (JNJ), Sanofi SA (ADR) (SNY): Health Care Investment Ideas From Warren Buffett
Famed investor Warren Buffett once called the high cost of health care a "tapeworm eating at our economic body." While he might be disgusted by the costs, it hasn't stopped ...
VIVUS, Inc. (VVUS), ISIS Pharmaceuticals, Inc. (ISIS), Gilead Sciences, Inc. (GILD): Biotech Companies Battle It Out
Biotech companies sometimes get lucky, launching a drug into a new indication where there's no competition, but more often than not the biotech companies have to battle it out...
The Procter & Gamble Company (PG): Can’t Sleep? Don’t Worry, You’re Not Alone
Blame it on a "case of the Mondays" or perhaps a rough night out on the town, but for many of us getting a good night's rest isn't nearly as simple as it sounds.
Hedge Funds Are Betting On Pfizer Inc. (PFE)
Pfizer Inc. (NYSE:PFE) was in 81 hedge funds' portfolio at the end of the first quarter of 2013. PFE shareholders have witnessed an increase in hedge fund interest recently.
Pipeline Probe: Alnylam Pharmaceuticals, Inc. (ALNY)
Shares of biotech Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have soared over 160% in the past year.
Sanofi SA (ADR) (SNY), Bristol Myers Squibb Co. (BMY): The Diabetes Drug War
Technological advances have allowed for people to have more longevity. Drug companies research and develop medicines to prevent, control and cure diseases.
Eli Lilly & Co. (LLY): Is a Type 1 Diabetes Cure Right Around the Corner?
For lack of a better phrase, those who have type 1 diabetes -- a form of diabetes whereby the person's own autoimmune system attacks or attempts to destroy cells in the pancreas...
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Top Treatments for High Cholesterol
About a third of American adults have high LDL cholesterol -- that's the bad kind -- but less than half of adults with high LDL seek treatment, according to the Centers for Disease...
Biogen Idec Inc. (BIIB), Sanofi SA (ADR) (SNY): A Must Have Pharma Stock
After a year-long dream run, Biogen Idec Inc. (NASDAQ:BIIB) lost 5.25% in the week ended Friday, June 7.
NIKE, Inc. (NKE), Jabil Circuit, Inc. (JBL): The 3 Countries Stealing China’s Business
"Made in China." It's a slogan emblematic of many things – of cheap labor, of the loss of U.S.
Bristol Myers Squibb Co (BMY), Momenta Pharmaceuticals, Inc. (MNTA): White Collar Criminals Love Biotech Stocks
It's understandably very tempting for people with inside information to trade biotech stocks.
Why The Pfizer Inc. (PFE)-Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Settlement Affects the Whole Industy
Generic-drug makers are always on the hunt for the next branded drug to take down.
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Does This Pipeline Promise Tomorrow’s Blockbuster Sales?
Nearly every big pharma player has been hit with patent expirations that have hit hard on sales lately, and Merck & Co., Inc. (NYSE:MRK) is no exception. Merck & Co., Inc.
NPS Pharmaceuticals, Inc. (NPSP), Pfizer Inc. (PFE): The Profitable Business of Developing Orphan Drugs
"Making every patient count" is a catchy phrase that is perhaps most meaningful for biotech companies like NPS Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp. (SNTA): A Promising Biotech Stock for 2013
Biotechnology stocks offer investors some of the highest potential for returns of any industry.
Aegerion Pharmaceuticals, Inc. (AEGR), MannKind Corporation (MNKD): 3 Biotech Companies You Should Have Bought This Year
If you'd owned these three biotech companies at the beginning of the year, you're sitting on around a triple compared to a relatively smaller-but-still-impressive 34% increase...
Novartis AG (ADR) (NVS), Sanofi SA (ADR) (SNY): Pharma Big Wigs Warm Up to Africa’s $40 Billion Opportunity
For a long time, Africa’s traditional enemy with regard to diseases have been communicable diseases like HIV and Malaria. Now, however, this trend is changing.
Hedge Funds Are Selling GlaxoSmithKline plc (ADR) (GSK)
If you'd ask most stock holders, hedge funds are assumed to be underperforming, outdated financial vehicles of yesteryear.
Pfizer Inc. (PFE), Zoetis Inc (ZTS): 4 Investment Opportunities in Animal Health
Pfizer Inc. (NYSE:PFE) recently announced plans to sell its remaining 80% stake in animal-health company Zoetis Inc (NYSE:ZTS) after about four months on the public market.
Dendreon Corporation (DNDN): This Cancer Drug Developer Could Really Use a Partner
As we've learned over the past few years, getting a drug approved by the Food and Drug Administration is just half the battle in the biotech sector.
Sanofi SA (ADR) (SNY), GlaxoSmithKline plc (ADR) (GSK), Johnson & Johnson (JNJ): 5 Costliest Microbes in Financial History
The field of synthetic biology is still in its infancy, with many of the most promising companies residing outside of public markets, but make no mistake: The bioeconomy is on...
Hedge Funds Are Dumping GlaxoSmithKline plc (ADR) (GSK)
GlaxoSmithKline plc (ADR) (NYSE:GSK) was in 18 hedge funds' portfolio at the end of March. GSK investors should be aware of a decrease in enthusiasm from smart money lately.
Why Aegerion Pharmaceuticals, Inc. (AEGR) Shares Jumped
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Merck & Co., Inc. (MRK): New Sleeping Aid Could Be an Awakening for This Pharma Giant
A recent review published online in the journal, The Lancet, found nearly a quarter of all adults are unhappy with their sleep patterns.
This Metric Says You Are Smart to Buy Sanofi SA (ADR) (SNY)
To most investors, hedge funds are seen as slow, outdated financial vehicles of the past.
AstraZeneca plc (ADR) (AZN), GlaxoSmithKline plc (ADR) (GSK), Merck & Co., Inc. (MRK), Eli Lilly & Co. (LLY), AbbVie Inc (ABBV): The 5 Highest-Paying Dividend Stocks in Big Pharma
Any investor looking for the highest-paying dividend stocks would do well to start in Big Pharma, where many of the top picks offer yields in excess of 3% or 4%.
GlaxoSmithKline plc (ADR) (GSK), Sanofi SA (ADR) (SNY), Theravance Inc (THRX): This Week in Biotech
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Is Aegerion Pharmaceuticals, Inc. (AEGR) Now a Sell?
Shares of Aegerion Pharmaceuticals, Inc.
Zoetis Inc (ZTS), Pfizer Inc. (PFE): What About The Competition?
Dividend stocks are everywhere, but many just downright stink. In some cases, the business model is in serious jeopardy, or the dividend itself isn't sustainable.
MannKind Corporation (MNKD): Why Have Shares Moved?
MannKind Corporation (NASDAQ:MNKD) took one giant leap over the past few days.
Pfizer Inc. (PFE), Sanofi SA (ADR) (SNY), Onyx Pharmaceuticals, Inc. (ONXX): Will ASCO Unlock Big Value in This Cancer Drug Class?
Avastin -- which the Food and Drug Administration has approved to treat metastatic colorectal cancer (as a first-line and second-line treatment), metastatic HER2-negative breast...
MannKind Corporation (MNKD): Should You Buy?
Perennial underdog MannKind Corporation (NASDAQ:MNKD) could be on its countdown to liftoff.
VIVUS, Inc. (VVUS): You’ve Got To Spend Money To Make Money
VIVUS, Inc. (NASDAQ:VVUS) has the first part down.
NPS Pharmaceuticals, Inc. (NPSP), Vertex Pharmaceuticals Incorporated (VRTX): Double-Digit Returns from the Biotechnology Strategy
Investments in biotechnology by the average investor tend to deliver hit or miss returns over time.
Regeneron Pharmaceuticals Inc (REGN), Questcor Pharmaceuticals Inc (QCOR), Aegerion Pharmaceuticals, Inc. (AEGR): Three Booming Biotech Companies
Wall Street had a great week. The Dow topped 15,000. The S&P 500 also notched a record high. But few stocks blew the doors off like those of these three biotech companies.
Merck & Co., Inc. (MRK): Three Promising Treatments for a Surprisingly Common Health Problem
It's that time of year. The sounds of sneezing, coughing, and sniffling can be heard across America. Around 40 million people in the U.S.
Amgen, Inc. (AMGN): What’s Its Next Catalyst?
Amgen, Inc. (NASDAQ:AMGN) stock has been on a bit of a roller coaster lately.
Regeneron Pharmaceuticals Inc (REGN), Sanofi SA (SNY), Arena Pharmaceuticals, Inc. (ARNA) & Three Companies Ripe for a Takeover
One of the nice things about owning biotech companies is the large number of acquisitions in the sector.
Biogen Idec Inc. (BIIB) Bounces Higher
If you thought that the great run so far in 2013 was over for Biogen Idec Inc. (NASDAQ:BIIB), think again.
Novartis AG (ADR) (NVS), Sanofi SA (ADR) (SNY), Regeneron Pharmaceuticals Inc (REGN): Three Potential Game Changers for America’s No. 1 Killer
Heart disease kills nearly 600,000 Americans every year, making it the nation's No. 1 cause of death, according to the Centers for Disease Control and Prevention.
Aegerion Pharmaceuticals, Inc. (AEGR), Raptor Pharmaceutical Corp. (RPTP): Two Orphan Drugmakers With Upcoming Catalysts
Within the next few days, stocks for two orphan drugmakers could either soar or sink. Both Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and Raptor Pharmaceutical Corp.
General Motors Company (GM), Sanofi SA (ADR) (SNY): Ex-Lehman Hedge Fund’s Favorite Equities
Managed by the former head of Global Trading Strategies for Lehman Brothers, Realm Partners was started in 2009 by Robert Millard with $650 million.
